PALSONIFY (paltusotine) by Crinetics Pharmaceuticals is somatostatin, paltusotine suppresses growth hormone (gh) and insulin-like growth factor-1 (igf-1) secretion. Approved for acromegaly. First approved in 2025.
Drug data last refreshed 19h ago
somatostatin, paltusotine suppresses growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion. Paltusotine exerts its pharmacological activity via selective agonism (>4000-fold) at somatostatin receptor 2 (SSTR2) and exhibits little or no affinity for other SST receptor subtypes.…
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
Worked on PALSONIFY at Crinetics Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo